Prodromal Alzheimer's disease

• Roche

  Company1 trialPhase 3119 people

• AC Immune

  Company1 trialPhase 1/2304 people

• Paul S. Aisen

  1 trialPhase 2450 people

• Sunnybrook Health Sciences Centre

  1 trialPhase 240 people

• Emory University

  1 trial76 people

National Institute on AgingUS$12.2mNational Institute of Neurological Disorders and StrokeUS$706.3k

• Association of the in Utero Exposome with Life-Course Cognition and Prodromal Alzheimer's Disease in Midlife.

  National Institute of Neurological Disorders and StrokePublic Health InstituteUS$706.3k2022–2027

• Microglia targeted interventions in prodromal Alzheimer's disease stage

  National Institute on AgingBoston University Medical CampusUS$782.1k2023–2028

• In vivo Identification of Pre-Atrophic Brain Neurodegeneration in Prodromal Alzheimer Disease with Quantitative Gradient Recalled Echo MRI

  National Institute on AgingWashington UniversityUS$712.5k2022–2027

• Low Neurophysiologic Resistance to Anesthetics as a Marker of Preclinical/Prodromal Alzheimer's Disease and Neurovascular Pathology, Delirium risk and Inattention

  National Institute on AgingDuke UniversityUS$704k2022–2026

• Identification of early transcriptional and pathological changes undergone by vulnerable brain regions during prodromal Alzheimer's disease

  National Institute on AgingBoston University Medical CampusUS$459.1k2024–2026

• Neuromodulation of brain network function in preclinical and prodromal Alzheimer's Disease

  National Institute on AgingMassachusetts General HospitalUS$210k2023–2027

• Advanced MR Imaging of Olfactory Impairment in Prodromal Alzheimer's Disease

  National Institute on AgingHugo W. Moser Res Inst Kennedy KriegerUS$753.9k2020–2027

• Dissociating the mechanisms of Tau PET and cortical atrophy underlying memory deficits in typical and atypical prodromal Alzheimer's disease

  National Institute on AgingMassachusetts General HospitalUS$180.2k2020–2026

• Partnered Rhythmic Rehabilitation for Enhanced Motor-Cognition in Prodromal Alzheimer's Disease

  National Institute on AgingEmory UniversityUS$681.6k2019–2025

• Behavioral and Neural Indicators of Prodromal Alzheimer's Disease

  National Institute on AgingUniversity of Massachusetts AmherstUS$2.5k2019–2022